Clinical Trial Update: A Study of the Safety and Efficacy of EBV Specific T-cell Lines [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluated the safety and efficacy of Epstein-Barr virus–specific T-cell lines in patients with Epstein-Barr virus infections and pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infections
• Lymphoma
• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• EBV-specific T-cell lines

Snippet

Sponsor: Dr. Jean-Sebastien Delisle, MD, PhD | Conditions: Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder | Phase 1, Phase 2 | Status: COMPLETED